<a href="https://www.medchemexpress.com/SB290157_trifluoroacetate.html">SB290157 (trifluoroacetate)</a>产品描述:SB290157 trifluoroacetate is a potent and selective <b>C3a</b> receptor antagonist with an <b>IC<sub>50</sub></b> of 200 nM. IC50 & Target: IC50: 200 nM (C3a)<sup>[1]</sup> <i><b>In Vitro:</b></i> SB 290157, functions as a competitive antagonist of <sup>125</sup>I-C3a radioligand binding to rat basophilic leukemia-2H3 cells expressing the human C3aR (RBL-C3aR), with an IC<sub>50</sub> of 200 nM. SB 290157 blocks C3a-induced C3aR internalization in a concentration-dependent manner and C3a-induced Ca<sup>2+</sup> mobilization in RBL-C3aR cells and human neutrophils with IC<sub>50</sub>s f 27.7 and 28 nM, respectively. SB 290157 is selective for the C3aR in that it does not antagonize the C5aR or six other chemotactic G protein-coupled receptors. SB 290157 also inhibits C3a-induced Ca<sup>2+</sup> mobilization of RBL-2H3 cells expressing the mouse and guinea pig C3aRs. It potently inhibits C3a-mediated ATP release from guinea pig platelets and inhibits C3a-induced potentiation of the c<br><br> <br> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介绍:MedChemExpress(MCE)专注于各种抑制剂、激动剂、API及化合物库,总部位于美国新泽西,分别在瑞典和上海设有欧洲区子公司和亚洲区总代理,营销网点遍及全球20多个国家地区。MCE经过多年努力已成为全球生物活性小分子领域的一流供应商, 产品涵盖癌症、神经科学、抗感染、表观遗传学等20个热门研究领域,PI3K、MAPK等近千个细分靶点,超过4000个活性小分子化合物现货,以及GPCR、API、离子通道等超过20种不同类型的化合物库,同时提供从毫克到千克的专业定制合成服务。</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 对每批产品都进行严格的LCMS和NMR检验,其产品已被全球近万名客户广泛使用并发表大量文章、专利;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各领域热门抑制剂、激动剂,不断扩增已有化合物库,以满足最新的科研需求;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">数千种产品在上海有充足备货,24-48小时内送达客户;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量产品提供免费试用装;</span> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);"> 已为全球多个知名企业、院校构建各种定制型化合物库。</span><br><br>产品链接:<a href="http://www.medchemexpress.cn/sb290157-trifluoroacetate.html">www.medchemexpress.cn/sb290157-trifluoroacetate.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt=""> |
SB290157 (trifluoroacetate)研究进
发布日期:2017-10-30 浏览次数:0
核心提示:a href=https://www.medchemexpress.com/SB290157_trifluoroacetate.htmlSB290157 (trifluoroacetate)/a产品描述:SB290157 trif
- 下一篇:暂无
- 上一篇:MT-DADMe-ImmA研究进展
行业动态
更多...
- SB290157 (trifluoroaceta 10-30
- MT-DADMe-ImmA研究进展 10-30
- LY3214996研究进展 10-30
- SUN11602研究进展 10-30
- GPR120-IN-1研究进展 10-30
- PDE1-IN-2研究进展 10-30
- LF3研究进展 10-30
- Emodepside研究进展 10-30
- BGB-3111研究进展 10-30
- AK-1研究进展 10-30